deltatrials
Completed PHASE2 INTERVENTIONAL 6-arm NCT01928576

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (NA_00084192)

A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer.

Sponsor: Bristol-Myers Squibb

Conditions Epigenetic Therapy Non-Small Cell Lung Cancer
Interventions Azacitidine CC-486 300 Entinostat Nivolumab
Updated 20 times since 2017 Last updated: May 1, 2024 Started: Nov 6, 2013 Primary completion: Apr 4, 2023 Completion: Apr 4, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01928576, this PHASE2 trial focuses on Epigenetic Therapy and Non-Small Cell Lung Cancer and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 20 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Oct 2017 · 5 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jul 2019 · 9 months · monthly snapshot~Jul 2019 – ~Oct 2019 · 3 months · monthly snapshot~Oct 2019 – ~May 2020 · 7 months · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Jul 2023 · 5 months · monthly snapshot~Jul 2023 – ~Jun 2024 · 11 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jul 2023 — Jun 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 15 earlier versions

  1. Feb 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  4. Sep 2021 — Jul 2022 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  6. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  7. May 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  8. Oct 2019 — May 2020 [monthly]

    Recruiting PHASE2

  9. Jul 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  10. Oct 2018 — Jul 2019 [monthly]

    Recruiting PHASE2

  11. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  12. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  13. May 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  14. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Celgene
  • Rhone-Poulenc Rorer
  • Rising Tide Foundation
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Stand Up To Cancer
  • Syndax Pharmaceuticals
Data source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations